Lebrikizumab boosts lung function in asthma

LOS ANGELES – The investigational interleukin-13 inhibitor lebrikizumab provides a clinically meaningful improvement in measures of lung function within 1 week after the first dose in patients with...
Source: Family Practice News - Category: Primary Care Source Type: news